For Patients

Leading with science to transform patients' lives

At Immunocore, we strive to continue our mission of improving patient outcomes for all forms of cancer, infectious diseases and autoimmune conditions. Our commitment to patients inspires and drives our pharmaceutical breakthroughs to transform the lives of people with serious diseases.

Providing new hope with clinical trials

We are currently conducting multiple clinical trials with diverse candidates, indications, and phases for patients. All clinical trials are open to patients who are eligible.

View our clinical trials

Select advanced solid tumors clinical trial

IMC-F106C is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.

Advanced melanoma clinical trial

To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1) vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma.

Chronic HIV infection clinical trial

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Hepatitis B, chronic clinical trial

IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB). This is the first in-human study of IMC-I109V in persons with CHB.

Expanded Access Policy

Explore our additional resource for clinical trials

If there is a medical circumstance where a patient has been denied clinical trial access, but is facing a serious condition or exhausted all available treatment options, regulators may allow companies to administer medications outside of a clinical trial setting.

We may allow patients access to our treatments where there is sufficient evidence to provide the pharmaceutical use in particular situations. The decision to give expanded access is consistent with applicable laws and regulations and is aligned with FDA guidelines. A request must be sent from the patient and meet the following criteria:

  • The patient has a serious or life-threatening disease
  • The patient is ineligible for an ongoing clinical trial of that investigational treatment
  • The patient's disease is similar to the indication(s) for which the investigational treatment is currently being evaluated in pivotal study(ies)
  • No comparable therapies (investigational or approved) are available
  • Immunocore must be able to review data from certain completed studies to determine whether, for patients with disease or condition to be treated, the potential benefits of the investigational treatment outweigh the potential risks.
  • There is an adequate supply of the investigational treatment
  • It is logistically feasible to make the investigational treatment available and it can be safely administered in a controlled setting. The referring physician must refer to a physician and site experienced with the safe use of an ImmTAC product via clinical study(ies) participation.
  • Physician is willing to complete and adhere to regulatory mechanism for access, and have adequate staff and facilities to safely administer and monitor patient.
  • The treatment plan and required observation/follow-up (inclusion/exclusion criteria, treatment plan, follow-up and safety monitoring) must be adhered as provided.
  • Required informed consent must be obtained
  • The expanded access to the investigational treatment will not in any way compromise the planned development or interfere with the regulatory approval process

All requests for expanded access can be made out to and must be approved by a qualified and licensed physician.

Contact us

If you are a patient and would like additional information, please contact us with any inquiries or questions.